tradingkey.logo
tradingkey.logo
Suchen

ANI Pharmaceuticals Inc

ANIP
Zur Watchlist hinzufügen
83.050USD
+0.270+0.33%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
1.89BMarktkapitalisierung
20.19KGV TTM

mehr Informationen über ANI Pharmaceuticals Inc Unternehmen

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc Informationen

BörsenkürzelANIP
Name des UnternehmensANI Pharmaceuticals Inc
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)
Anzahl der mitarbeiter897
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
Addresse210 Main Street West
StadtBAUDETTE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl56623
Telefon12186343500
Websitehttps://www.anipharmaceuticals.com/
BörsenkürzelANIP
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)

Führungskräfte von ANI Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
38.43K
-36.36%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.39K
-1.23%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
29.51K
+14.76%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
11.22K
+38.83%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von ANI Pharmaceuticals Inc?

Die fünf größten Anteilseigner von ANI Pharmaceuticals Inc sind: Mr. Chad Gassert

Wie viele Institutionen halten Anteile an ANI Pharmaceuticals Inc (ANIP)?

Mit Stand vom 2026Q1 halten 555 Institutionen Anteile an ANI Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 23.15M, was 101.74% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 57726.00 gestiegen.

Was ist die größte Einnahmequelle von ANI Pharmaceuticals Inc?

Am 2026Q1 erzielte das Geschäft mit Sales of generic pharmaceutical products für ANI Pharmaceuticals Inc den höchsten Umsatz in Höhe von 384.11M, was 43.48% des Gesamtumsatzes entspricht.